Literature DB >> 14660751

Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.

Myriam Alcalay1, Natalia Meani, Vania Gelmetti, Anna Fantozzi, Marta Fagioli, Annette Orleth, Daniela Riganelli, Carla Sebastiani, Enrico Cappelli, Cristina Casciari, Maria Teresa Sciurpi, Angela Rosa Mariano, Simone Paolo Minardi, Lucilla Luzi, Heiko Muller, Pier Paolo Di Fiore, Guido Frosina, Pier Giuseppe Pelicci.   

Abstract

Acute myelogenous leukemias (AMLs) are genetically heterogeneous and characterized by chromosomal rearrangements that produce fusion proteins with aberrant transcriptional regulatory activities. Expression of AML fusion proteins in transgenic mice increases the risk of myeloid leukemias, suggesting that they induce a preleukemic state. The underlying molecular and biological mechanisms are, however, unknown. To address this issue, we performed a systematic analysis of fusion protein transcriptional targets. We expressed AML1/ETO, PML/RAR, and PLZF/RAR in U937 hemopoietic precursor cells and measured global gene expression using oligonucleotide chips. We identified 1,555 genes regulated concordantly by at least two fusion proteins that were further validated in patient samples and finally classified according to available functional information. Strikingly, we found that AML fusion proteins induce genes involved in the maintenance of the stem cell phenotype and repress DNA repair genes, mainly of the base excision repair pathway. Functional studies confirmed that ectopic expression of fusion proteins constitutively activates pathways leading to increased stem cell renewal (e.g., the Jagged1/Notch pathway) and provokes accumulation of DNA damage. We propose that expansion of the stem cell compartment and induction of a mutator phenotype are relevant features underlying the leukemic potential of AML-associated fusion proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660751      PMCID: PMC281638          DOI: 10.1172/JCI17595

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  In vitro base excision repair assay using mammalian cell extracts.

Authors:  G Frosina; E Cappelli; P Fortini; E Dogliotti
Journal:  Methods Mol Biol       Date:  1999

Review 2.  Regulation of granulopoiesis by transcription factors and cytokine signals.

Authors:  A C Ward; D M Loeb; A A Soede-Bobok; I P Touw; A D Friedman
Journal:  Leukemia       Date:  2000-06       Impact factor: 11.528

3.  Fringe is a glycosyltransferase that modifies Notch.

Authors:  D J Moloney; V M Panin; S H Johnston; J Chen; L Shao; R Wilson; Y Wang; P Stanley; K D Irvine; R S Haltiwanger; T F Vogt
Journal:  Nature       Date:  2000-07-27       Impact factor: 49.962

4.  Human EVI9, a homologue of the mouse myeloid leukemia gene, is expressed in the hematopoietic progenitors and down-regulated during myeloid differentiation of HL60 cells.

Authors:  Y Saiki; Y Yamazaki; M Yoshida; O Katoh; T Nakamura
Journal:  Genomics       Date:  2000-12-15       Impact factor: 5.736

5.  Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.

Authors:  V Sexl; R Piekorz; R Moriggl; J Rohrer; M P Brown; K D Bunting; K Rothammer; M F Roussel; J N Ihle
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  p45(NFE2) is a negative regulator of erythroid proliferation which contributes to the progression of Friend virus-induced erythroleukemias.

Authors:  Y J Li; R R Higgins; B J Pak; R A Shivdasani; P A Ney; M Archer; Y Ben-David
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

7.  Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.

Authors:  Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

8.  Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage.

Authors:  E Passegué; W Jochum; M Schorpp-Kistner; U Möhle-Steinlein; E F Wagner
Journal:  Cell       Date:  2001-01-12       Impact factor: 41.582

Review 9.  Overexpression of enzymes that repair endogenous damage to DNA.

Authors:  G Frosina
Journal:  Eur J Biochem       Date:  2000-04

10.  The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells.

Authors:  F N Karanu; B Murdoch; L Gallacher; D M Wu; M Koremoto; S Sakano; M Bhatia
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

View more
  101 in total

1.  GATA-1 utilizes Ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis.

Authors:  Julie Ross; Lionel Mavoungou; Emery H Bresnick; Eric Milot
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

2.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

3.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

4.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

5.  ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.

Authors:  Daniela Salat; Robert Liefke; Jörg Wiedenmann; Tilman Borggrefe; Franz Oswald
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

Review 6.  The DNA damage response pathway in normal hematopoiesis and malignancies.

Authors:  Domenico Delia; Shuki Mizutani
Journal:  Int J Hematol       Date:  2017-07-13       Impact factor: 2.490

7.  Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures.

Authors:  Matthew J Walter; John S Park; Steven K M Lau; Xia Li; Andrew A Lane; Rakesh Nagarajan; William D Shannon; Timothy J Ley
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

9.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

10.  Transcription factor ELF4 controls the proliferation and homing of CD8+ T cells via the Krüppel-like factors KLF4 and KLF2.

Authors:  Takeshi Yamada; Chun Shik Park; Maksim Mamonkin; H Daniel Lacorazza
Journal:  Nat Immunol       Date:  2009-05-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.